OKYO Pharma Limited, a preclinical biopharmaceutical company, is engaged in developing therapies for patients suffering from inflammatory eye diseases and eye pain in the UK. The company is headquartered in London, the United Kingdom.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-6.69M |
| EBITDA | $-8.50M |
| Operating Margin | 0.00% |
| Return on Equity | -263.80% |
| Return on Assets | -43.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.23 |
| Price-to-Book | 5.53 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.29 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $52.48M |
| Float | $27.94M |
| % Insiders | 31.13% |
| % Institutions | 20.10% |
Volatility is currently contracting
OKYO Pharma Ltd (NASDAQ:OKYO) enrolled the first patients in its Phase 3 trial of urcosimod for neuropathic corneal pain, a chronic and often severe eye condition with no FDA-approved treatment, the company said on Tuesday. The registrational NEPTUNE study has activated its first US site, with additional sites opening throughout medical centers across the country, OKYO said.
LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced first patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP).
LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.
LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in the 5th Annual ESCRS iNovation Day.
LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Cantor Global Healthcare Conference being held September 9-11, 2026.
LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company's ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary shares. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market.
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Non-Executive Director, John Brancaccio has purchased 5,000 of the Company's ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company's ordinary shares on NASDAQ at $1.54 per share.
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 22,500 ordinary shares at $1.45 per share, bringing his total holding to 10,873,916 ordinary shares, which is 20.55% of issued share capital.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OKYO and any ticker you trade — then tracks every position and per-strategy win rate.
